跳至主要内容
临床试验/EUCTR2005-002965-35-FI
EUCTR2005-002965-35-FI进行中(未招募)不适用

Safety of the Inactivated, Split-Virion Influenza Vaccine Administered by the Intradermal Route in Healthy Children

Sanofi Pasteur SA0 个研究点目标入组 100 人开始时间: 2005年7月11日最近更新:
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1) Aged 6 months to 8 years on the day of inclusion,
  • 2) Born at full term of pregnancy (>37 weeks) with a birth weight = 2.5 kg (infants and toddlers [<2 years] only),
  • 3) Informed consent form signed by the parent(s) or another legal representative (and by an independent witness if required by local regulations),
  • 4) Able to attend all scheduled visits and to comply with all trial procedures,
  • 5) Subject who completed vaccination according to the national immunization schedule.
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1) Febrile illness (rectal equivalent temperature = 38.0°C on the day of inclusion),
  • 2) Participation in another clinical trial in the four weeks preceding the first trial vaccination,
  • 3) Planned participation in another clinical trial during the present trial period,
  • 4) Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months, or long-term systemic corticosteroids therapy,
  • 5) Systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances,
  • 6) Chronic illness at a stage that could interfere with trial conduct or completion,
  • 7) Blood or blood-derived products received in the past three months,
  • 8) Previous vaccination against influenza with the trial vaccine or another vaccine,
  • 9) Any vaccination in the four weeks preceding the first trial vaccination,
  • 10) Vaccination planned in the four weeks following the trial vaccinations,
  • 11) Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination,
  • 12) History of seizures (Infants and toddlers [<2 years] only).

研究者

发起方
Sanofi Pasteur SA

相似试验

进行中(未招募)
1 期
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2009-2010 Formulation (Intradermal Route) - Immunogenicity and Safety of a Vaccine Against Influenza (2009-2010 Northern Hemisphere Season)Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intradermal route
EUCTR2009-009977-85-FRSanofi Pasteur SA131
进行中(未招募)
1 期
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intramuscular Route) - Immunogenicity and Safety of a Vaccine against Influenza (2010-2011 NH season, intramuscular route)Vaccination of adults up to 60 years of age an elderly of 61 years of age and over with inactivated split-virion influenza vaccine administerd by intramuscular route.
EUCTR2009-017690-38-FRSanofi Pasteur SA129
进行中(未招募)
不适用
Immunogenicity and Safety of the Influenza Vaccine (Split Virion, Inactivated), Northern Hemisphere 2010-2011 Formulation (Intradermal Route) - Immunogenicity and Safety of a Vaccine Against Influenza (2010-2011 NH season, intradermal route)
EUCTR2009-017688-40-BESanofi Pasteur SA
已完成
2 期
Trial to Describe the Safety and Immunogenicity of Fluzone®Influenza
NCT00524940Sanofi Pasteur, a Sanofi Company124
进行中(未招募)
1 期
Effictiveness and safety of vaccination with Live-attenuated Influenza Vaccine
EUCTR2015-003250-41-GBPublic Health England2,500